title: Natriuretic Peptides and the Management of Heart Failure.
abstract: Natriuretic peptide has been validated as a useful biomarker in the diagnosis of heart failure, although its role in guiding medical management of heart failure is not well established. We endeavored to determine if natriuretic peptide-guided therapy is associated with improved outcomes for heart failure patients. A total of 11 trials (2628 patients) comparing natriuretic peptide-guided therapy with standard therapy for heart failure patients were identified; follow-up times ranged from 3 months to 3 years. Our data indicate that natriuretic peptide levels and all-cause mortality rates do not appear to benefit from natriuretic peptide-guided therapy when compared with standard therapy. However, a decreased rate of cardiovascular events does appear to be associated with natriuretic peptide-guided therapy.
authors.forename: Tyler
authors.initials: T
authors.lastname: Kern
authors.forename: Ilan
authors.initials: I
authors.lastname: Kedan
authors.affiliation: David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.
authors.forename: Asher
authors.initials: A
authors.lastname: Kimchi
mesh_terms: D015415:Biomarkers / Q000097:blood; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D045265:Natriuretic Peptides / Q000097:blood*; D011237:Predictive Value of Tests; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D045265:Natriuretic Peptides